Isolated Systolic Hypertension in the Elderly and Very Elderly

Isolated Systolic Hypertension Clinical Trial

Official title:
Comparison of the Efficacy of Olmesartan Medoxomil Versus Nitrendipine on Systolic Blood Pressure in Elderly and Very Elderly Patients With Isolated Systolic Hypertension

Status Completed

Clinical Trial Summary

To evaluate the efficacy of long-term treatment of individually optimized doses of olmesartan medoxomil compared to nitrendipine in elderly and very elderly patients with isolated systolic hypertension. The study hypothesis is non-inferiority of olmesartan medoxomil compared to nitrendipine in lowering mean sitting systolic blood pressure after 12 weeks of treatment compared to baseline. The study duration is up to 32 weeks, including a 24-week treatment period. After 12 weeks hydrochlorothiazide may be added to control blood pressure. Efficacy and safety measurements are carried out at up to 15 visits during the trial period.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00751829
Study type	Interventional
Source	Daiichi Sankyo, Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	July 2003
Completion date	February 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01987284` - SER100 in Isolated Systolic Hypertension	Phase 2
Recruiting	`NCT05165251` - Blood Pressure and Lipids Reduction in High Risk Elderly Patients With Isolated Systolic Hypertension	Phase 4
Terminated	`NCT02088450` - Systolic Hypertension in Europe Placebo-Controlled Trial	Phase 2
Terminated	`NCT00802893` - Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction	Phase 2
Completed	`NCT01656408` - A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)	Phase 1